Clinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective study

Abstract Background The optimal management of patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) after progression on osimertinib includes cytotoxic chemotherapy. Continuing osimertinib therapy beyond progressive disease (PD) is occasionally adopted in r...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Issei Oi, Kohei Fujita, Takuma Imakita, Yuta Okada, Saiki Yoshimura, Naoki Fujimoto, Shogo Toyama, Atsuko Watanabe, Takanori Ito, Ryosuke Kaku, Osamu Kanai, Masatsugu Ohuchi, Tetsuo Noguchi, Mitsuhiro Tsukino, Satoru Sawai, Kiminobu Tanizawa
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-12-01
Edice:	BMC Cancer
Témata:	Osimertinib Beyond PD Best supportive care Retrospective study
On-line přístup:	https://doi.org/10.1186/s12885-025-15479-w
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!